Related references
Note: Only part of the references are listed.Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system
E. C. Vamvakas
VOX SANGUINIS (2012)
Establishment of the first International Repository for Transfusion-Relevant Bacteria Reference Strains: ISBT Working Party Transfusion-Transmitted Infectious Diseases (WP-TTID), Subgroup on Bacteria
M. Stoermer et al.
VOX SANGUINIS (2012)
Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials
J. Cid et al.
VOX SANGUINIS (2012)
Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients
Peter Schlenke et al.
ANNALS OF HEMATOLOGY (2011)
Anaphylactic reaction after methylene blue-treated plasma transfusion
P. Dewachter et al.
BRITISH JOURNAL OF ANAESTHESIA (2011)
Evaluation of platelet transfusion clinical trials - response to Corash & Sherman
Jean-Louis H. Kerkhoffs
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Evaluation of platelet transfusion clinical trials
Laurence Corash et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion
Miguel Lozano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period
Jean-Pierre Cazenave et al.
TRANSFUSION (2011)
Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets
Eleftherios C. Vamvakas
TRANSFUSION (2011)
Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment
Anne North et al.
TRANSFUSION (2011)
The extent of amotosalen photodegradation during photochemical treatment of platelet components correlates with the level of pathogen inactivation
Weiqun Liu et al.
TRANSFUSION (2011)
In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood
Jose A. Cancelas et al.
TRANSFUSION (2011)
The hemostatic efficacy of platelet components prepared with pathogen inactivation
Laurence Corash
TRANSFUSION (2011)
Clarify the negatives of the MIRASOL noninferiority trial reply
Raymond P. Goodrich
TRANSFUSION (2011)
Cesium cessation? An advantage of pathogen reduction treatments
Paul D. Mintz
TRANSFUSION (2011)
Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process
Jose A. Cancelas et al.
TRANSFUSION (2011)
Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue
Karine Nubret et al.
TRANSFUSION (2011)
Pathogen-inactivation of platelet components with the INTERCEPT Blood System™: A cohort study
Laura Infanti et al.
TRANSFUSION AND APHERESIS SCIENCE (2011)
Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates
Reinhard Henschler et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2011)
Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light
Susanne Marschner et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2011)
Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction
Jerard Seghatchian et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2011)
Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™
Johannes Irsch et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2011)
UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma
Axel Seltsam et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2011)
In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP plus photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™)
P. Chavarin et al.
VOX SANGUINIS (2011)
Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products
Raymond P. Goodrich et al.
BIOLOGICALS (2010)
Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC
N. A. Mufti et al.
BIOLOGICALS (2010)
Dose of Prophylactic Platelet Transfusions and Prevention of Hemorrhage
Sherrill J. Slichter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment
Jean-Pierre Cazenave et al.
TRANSFUSION (2010)
White blood cell inactivation after treatment with riboflavin and ultraviolet light
Susanne Marschner et al.
TRANSFUSION (2010)
Defining adequate pathogen reduction performance for transfused blood components
Raymond P. Goodrich et al.
TRANSFUSION (2010)
A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology
J. -P Cazenave et al.
TRANSFUSION (2010)
The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model
Brian Custer et al.
TRANSFUSION (2010)
Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system
M. El-Ekiaby et al.
TRANSFUSION MEDICINE (2010)
Monitoring photochemical pathogen inactivation treatment using amotosalen and ultraviolet-A light: evaluation of an indicator label
H. Isola et al.
VOX SANGUINIS (2010)
Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light
Stephen J. Wagner et al.
TRANSFUSION (2009)
Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use
Jean Claude Osselaer et al.
TRANSFUSION (2009)
Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats
Vic Ciaravino et al.
TRANSFUSION (2009)
Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies
Susanne M. Picker et al.
TRANSFUSION (2009)
Emerging infectious disease agents and their potential threat to transfusion safety
Susan L. Stramer et al.
TRANSFUSION (2009)
Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates
Daniel R. Ambruso et al.
TRANSFUSION (2009)
Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop
Harvey G. Klein et al.
TRANSFUSION (2009)
Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La REunion
Patrice Rasongles et al.
TRANSFUSION (2009)
Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light
Harald Mohr et al.
TRANSFUSION (2009)
A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light
Harald Mohr et al.
TRANSFUSION (2009)
Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study
Susanne M. Picker et al.
TRANSFUSION AND APHERESIS SCIENCE (2009)
Properties of Pathogen-Inactivated Plasma Components
Christopher Prowse
TRANSFUSION MEDICINE REVIEWS (2009)
Study of coagulation function in thawed apheresis plasma for photochemical treatment by amotosalen and UVA
N. de Valensart et al.
VOX SANGUINIS (2009)
Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura:: a multicentric, prospective cohort study
Julio del Rio-Garma et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment
Jean C. Osselaer et al.
TRANSFUSION (2008)
Spore-forming organisms in platelet concentrates: a challenge in transfusion bacterial safety
M. Stoermer et al.
TRANSFUSION MEDICINE (2008)
Epidemiology of transfusion related acute lung injury in France: Preliminary results
Philippe Renaudier et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2008)
Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation
Heather L. Reddy et al.
TRANSFUSION MEDICINE REVIEWS (2008)
ADAMTS-13 activity and von Willebrand factor levels in methylene blue photo-inactivated plasma processed by either the Springe method or an 'in house' system
J. del Rio-Garma et al.
VOX SANGUINIS (2008)
Quantification of viral inactivation by photochemical treatment with amotosalen and UV a light, using a novel polymerase chain reaction inhibition method with preamplification
Jean-Pierre Allain et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Viability of red cells prepared with S-303 pathogen inactivation treatment
Jorge A. Rios et al.
TRANSFUSION (2006)
A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura
Paul D. Mintz et al.
TRANSFUSION (2006)
The Mirasol TM PRT system for pathogen reduction of platelets and plasma:: An overview of current status and future trends
Raymond P. Goodrich et al.
TRANSFUSION AND APHERESIS SCIENCE (2006)
Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function
Yasmin Singh et al.
TRANSFUSION (2006)
Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia
SJ Slichter et al.
TRANSFUSION (2006)
Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease
PD Mintz et al.
BLOOD (2006)
Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study
AC Simonsen et al.
TRANSFUSION (2006)
Assessment of the economic value of the INTERCEPT blood system in Belgium
K Moeremans et al.
TRANSFUSION MEDICINE (2006)
In vitro evaluation of Haemonetics MCS plus apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set
H Isola et al.
VOX SANGUINIS (2006)
Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light
S Murphy et al.
TRANSFUSION (2006)
Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial
E Snyder et al.
TRANSFUSION (2005)
Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients
RJ Benjamin et al.
TRANSFUSION (2005)
Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands
MJ Postma et al.
TRANSFUSION MEDICINE (2005)
Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment
L Lin et al.
TRANSFUSION (2005)
Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set
K Janetzko et al.
TRANSFUSION (2005)
Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction
JP AuBuchon et al.
TRANSFUSION (2005)
Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies
P de Alarcon et al.
TRANSFUSION (2005)
Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura
A Alvarez-Larrán et al.
VOX SANGUINIS (2004)
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial
J McCullough et al.
BLOOD (2004)
Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution
DJ van Rhenen et al.
TRANSFUSION MEDICINE (2004)
Recovery and life span of 111indium-radiolabelled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light
E Snyder et al.
TRANSFUSION (2004)
Riboflavin and UV-light based pathogen reduction: Extent and consequence of DNA damage at the molecular level
V Kumar et al.
PHOTOCHEMISTRY AND PHOTOBIOLOGY (2004)
Economics of pathogen inactivation technology for platelet concentrates in Japan
U Staginnus et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2004)
Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light
PH Ruane et al.
TRANSFUSION (2004)
Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease
L Corash et al.
BONE MARROW TRANSPLANTATION (2004)
In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days
R Moog et al.
JOURNAL OF CLINICAL APHERESIS (2004)
Targeting DNA and RNA in pathogens: Mode of action of amotosalen HCl
S Wollowitz
TRANSFUSION MEDICINE AND HEMOTHERAPY (2004)
The role of toxicology assessment in transfusion medicine
V Ciaravino et al.
TRANSFUSION (2003)
Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?
LM Williamson et al.
TRANSFUSION (2003)
Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States
CF Bell et al.
CLINICAL THERAPEUTICS (2003)
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment:: the euroSPRITE trial
D van Rhenen et al.
BLOOD (2003)
Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma
GF Riedler et al.
VOX SANGUINIS (2003)
Preclinical safety profile of plasma prepared using the INTERCEPT Blood System
V Ciaravino et al.
VOX SANGUINIS (2003)
Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin
J Hambleton et al.
TRANSFUSION (2002)
Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura
J de la Rubia et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time
RG Lerner et al.
VOX SANGUINIS (2000)
Share Paper
